{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:15:35Z","timestamp":1790946935743,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10557-025-07741-x","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T02:49:37Z","timestamp":1750819777000},"page":"725-734","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Factor XIa Inhibitors Versus Direct Oral Anticoagulants for Atrial Fibrillation: A Systematic Review and Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9236-0822","authenticated-orcid":false,"given":"Sufyan","family":"Shahid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9320-1228","authenticated-orcid":false,"given":"Minahil","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7229-0157","authenticated-orcid":false,"given":"Mariam","family":"Shahabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3199-7862","authenticated-orcid":false,"given":"Muhammad Abdullah","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2003-922X","authenticated-orcid":false,"given":"Allahdad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0019-6487","authenticated-orcid":false,"given":"Muhammad Ali","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamyial","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4356-5795","authenticated-orcid":false,"given":"Khadija","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"7741_CR1","doi-asserted-by":"publisher","unstructured":"Cheng S, He J, Han Y, Han S, Li P, Liao H, et al. Global burden of atrial fibrillation\/atrial flutter and its attributable risk factors from 1990 to 2021. EP Europace 2024;26:euae195. https:\/\/doi.org\/10.1093\/europace\/euae195.","DOI":"10.1093\/europace\/euae195"},{"key":"7741_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0002-9343(02)01236-6","volume":"113","author":"S Stewart","year":"2002","unstructured":"Stewart S, Hart CL, Hole DJ, McMurray JJV. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew\/Paisley study. Am J Med. 2002;113:359\u201364. https:\/\/doi.org\/10.1016\/S0002-9343(02)01236-6.","journal-title":"Am J Med"},{"key":"7741_CR3","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jacep.2018.02.021","volume":"4","author":"M Alkhouli","year":"2018","unstructured":"Alkhouli M, Alqahtani F, Aljohani S, Alvi M, Holmes DR. Burden of atrial fibrillation-associated ischemic stroke in the United States. JACC Clin Electrophysiol. 2018;4:618\u201325. https:\/\/doi.org\/10.1016\/j.jacep.2018.02.021.","journal-title":"JACC Clin Electrophysiol"},{"key":"7741_CR4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149:e1-156. https:\/\/doi.org\/10.1161\/CIR.0000000000001193.","journal-title":"Circulation"},{"key":"7741_CR5","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","volume":"76","author":"GF Tomaselli","year":"2020","unstructured":"Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants. JACC. 2020;76:594\u2013622. https:\/\/doi.org\/10.1016\/j.jacc.2020.04.053.","journal-title":"JACC"},{"key":"7741_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","volume":"78","author":"C Hsu","year":"2021","unstructured":"Hsu C, Hutt E, Bloomfield DM, Gailani D, Weitz JI. Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week. J Am Coll Cardiol. 2021;78:625\u201331. https:\/\/doi.org\/10.1016\/j.jacc.2021.06.010.","journal-title":"J Am Coll Cardiol"},{"key":"7741_CR7","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.jtha.2023.04.021","volume":"21","author":"JC Fredenburgh","year":"2023","unstructured":"Fredenburgh JC, Weitz JI. News at XI: moving beyond factor Xa inhibitors. J Thromb Haemost. 2023;21:1692\u2013702. https:\/\/doi.org\/10.1016\/j.jtha.2023.04.021.","journal-title":"J Thromb Haemost"},{"key":"7741_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/MOH.0b013e3283497e61","volume":"18","author":"F M\u00fcller","year":"2011","unstructured":"M\u00fcller F, Gailani D, Renn\u00e9 T. Factor XI and XII as antithrombotic targets. Curr Opin Hematol. 2011;18:349. https:\/\/doi.org\/10.1097\/MOH.0b013e3283497e61.","journal-title":"Curr Opin Hematol"},{"key":"7741_CR9","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","volume":"399","author":"JP Piccini","year":"2022","unstructured":"Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS, et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet. 2022;399:1383\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(22)00456-1.","journal-title":"Lancet"},{"key":"7741_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1056\/NEJMoa2406674","volume":"392","author":"CT Ruff","year":"2025","unstructured":"Ruff CT, Patel SM, Giugliano RP, Morrow DA, Hug B, Kuder JF, et al. Abelacimab versus rivaroxaban in patients with atrial fibrillation. N Engl J Med. 2025;392:361\u201371. https:\/\/doi.org\/10.1056\/NEJMoa2406674.","journal-title":"N Engl J Med"},{"key":"7741_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa2407105","volume":"392","author":"JP Piccini","year":"2025","unstructured":"Piccini JP, Patel MR, Steffel J, Ferdinand K, Van Gelder IC, Russo AM, et al. Asundexian versus apixaban in patients with atrial fibrillation. N Engl J Med. 2025;392:23\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2407105.","journal-title":"N Engl J Med"},{"key":"7741_CR12","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"7414","key":"7741_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"issue":"3","key":"7741_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986Sep 1;7(3):177\u201388. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2.","journal-title":"Control Clin Trials"},{"key":"7741_CR15","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1136\/bmj.l4898","volume":"28","author":"JA Sterne","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019Aug;28:366. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"7741_CR16","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1055\/a-2043-0346","volume":"123","author":"M Galli","year":"2023","unstructured":"Galli M, Laborante R, Ortega-Paz L, Franchi F, Rollini F, D\u2019Amario D, et al. Factor XI inhibitors in early clinical trials: a meta-analysis. Thromb Haemost. 2023;123:576\u201384. https:\/\/doi.org\/10.1055\/a-2043-0346.","journal-title":"Thromb Haemost"},{"key":"7741_CR17","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","volume":"133","author":"AW Koch","year":"2019","unstructured":"Koch AW, Schiering N, Melkko S, Ewert S, Salter J, Zhang Y, et al. MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood. 2019;133:1507\u201316. https:\/\/doi.org\/10.1182\/blood-2018-10-880849.","journal-title":"Blood"},{"key":"7741_CR18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2217\/fca-2023-0051","volume":"19","author":"N D\u2019Allesandro","year":"2023","unstructured":"D\u2019Allesandro N, Cave B, Hough A. Asundexian: an oral small molecule factor XIa inhibitor for the treatment of thrombotic disorders. Future Cardiol. 2023;19:477\u201386. https:\/\/doi.org\/10.2217\/fca-2023-0051.","journal-title":"Future Cardiol"},{"key":"7741_CR19","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1107039.","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07741-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07741-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07741-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T22:06:08Z","timestamp":1773698768000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07741-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7741"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07741-x","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"10 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval was required for this study design, as all data were obtained from publicly available sources.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.\u00a0","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}